Linus S. Lin
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Neuropeptides and Animal Physiology, Cannabis and Cannabinoid Research, Receptor Mechanisms and Signaling, Cell Adhesion Molecules Research, Chemical Synthesis and Analysis
Most-Cited Works
- → [18F]MK-9470, a positron emission tomography (PET) tracer forin vivohuman PET brain imaging of the cannabinoid-1 receptor(2007)313 cited
- → Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a Novel, Acyclic Cannabinoid-1 Receptor Inverse Agonist for the Treatment of Obesity(2006)122 cited
- → Antiobesity Efficacy of a Novel Cannabinoid-1 Receptor Inverse Agonist, N-[(1 S,2 S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), in Rodents(2007)101 cited
- → Regulation of Energy Homeostasis by Bombesin Receptor Subtype-3: Selective Receptor Agonists for the Treatment of Obesity(2010)87 cited
- → Addressing the metabolic activation potential of new leads in drug discovery: a case study using ion trap mass spectrometry and tritium labeling techniques(2003)77 cited
- → A facile microwave-assisted palladium-catalyzed cyanation of aryl chlorides(2006)75 cited
- → Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity(2010)65 cited
- → Discovery of MK-7725, A Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity(2012)62 cited
- → The discovery of sulfonylated dipeptides as Potent VLA-4 antagonists(2001)59 cited
- → Antiobesity Effect of MK-5046, a Novel Bombesin Receptor Subtype-3 Agonist(2010)49 cited